Ramipril Capsule
Product Images NDC 70518-3038

4 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 70518-3038). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Ramipril 10 mg oral capsules packaging label showing a quantity of 90 capsules. The label includes the product NDC 70518-3038, repackager RemedyRepack Inc., directions to store at 20-25°C with permitted excursions, and manufacturer details indicating Aurobindo Pharma Ltd., Hyderabad, India. The label notes 'Rx Only' and advises keeping medication out of children's reach.*
FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)
A line graph comparing the proportion of patients over days of follow-up for Ramipril versus placebo. The x-axis shows days of follow-up from 0 to approximately 1600, and the y-axis shows the proportion of patients from 0.00 to 0.20. The Ramipril line is solid and lies below the dashed placebo line, indicating fewer patients with the event over time on Ramipril. The graph includes a p-value of 0.0001.*
FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)
A forest plot chart comparing the relative risk of composite outcomes between placebo and Ramipril groups across various patient subgroups. The chart includes categories such as cardiovascular disease status, diabetes, age, sex, hypertension, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. Each subgroup shows number of patients, incidence rate in placebo group, and relative risk with 95% confidence intervals for the Ramipril group.*
FDA Label Image

Chemical Structure (Ramipril Str)

Chemical Structure (Ramipril Str)
Chemical structure diagram of ramipril showing its molecular components and bonds as presented in the image. The structure highlights rings, functional groups, and stereochemistry typical for ramipril.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.